Ophthalmology. Retina最新文献

{"title":"Clinical Outcomes in Neovascular Age-related Macular Degeneration with Aflibercept 8 mg in the Phase II CANDELA Study.","authors":"Jordana G Fein, Priya S Vakharia, A Paul Chous, Rutvi Desai, Fabiana Q Silva, Kimberly Reed, Alyson J Berliner, Robert Vitti, Charles C Wykoff","doi":"10.1016/j.oret.2025.03.023","DOIUrl":"10.1016/j.oret.2025.03.023","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abnormal Opacified Vitreous Humor Associated with Optic Disc Pit","authors":"Utsab Pan MS, FVRS, Romana Fazal DNB, FVRS, Abdul Mannan Mondal D.Optom","doi":"10.1016/j.oret.2024.09.001","DOIUrl":"10.1016/j.oret.2024.09.001","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Page e38"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Macular Neovascularization in Eyes Presenting with Macular Edema using OCT Angiography and a Deep Learning Model","authors":"Nida Wongchaisuwat MD ,&nbsp;Jie Wang PhD ,&nbsp;Elizabeth S. White MS ,&nbsp;Thomas S. Hwang MD ,&nbsp;Yali Jia PhD ,&nbsp;Steven T. Bailey MD","doi":"10.1016/j.oret.2024.10.017","DOIUrl":"10.1016/j.oret.2024.10.017","url":null,"abstract":"<div><h3>Purpose</h3><div>To test the diagnostic performance of an artificial intelligence algorithm for detecting and segmenting macular neovascularization (MNV) with OCT and OCT angiography (OCTA) in eyes with macular edema from various diagnoses.</div></div><div><h3>Design</h3><div>Prospective cross-sectional study.</div></div><div><h3>Participants</h3><div>Study participants with macular edema due to either treatment-naïve exudative age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO).</div></div><div><h3>Methods</h3><div>Study participants were imaged with macular 3 × 3–mm and 6 × 6–mm spectral-domain OCTA. Eyes with exudative AMD were required to have MNV in the central 3 × 3–mm area. A previously developed hybrid multitask convolutional neural network for MNV detection (aiMNV), and segmentation was applied to all images, regardless of image quality.</div></div><div><h3>Main Outcome Measures</h3><div>Sensitivity, specificity, positive predictive value, and negative predictive value of detecting MNV and intersection over union (IoU) score and F1 score for segmentation.</div></div><div><h3>Results</h3><div>Of 114 eyes from 112 study participants, 56 eyes had MNV due to exudative AMD and 58 eyes with macular edema due to either DME or RVO. The 3 × 3–mm OCTA scans with aiMNV detected MNV with 96.4% sensitivity, 98.3% specificity, 98.2% positive predictive value, and 96.6% negative predictive value. For segmentation, the average IoU score was 0.947, and the F1 score was 0.973. The 6 × 6–mm scans performed well; however, sensitivity for MNV detection was lower than 3 × 3–mm scans due to lower scan sampling density.</div></div><div><h3>Conclusions</h3><div>This novel aiMNV algorithm can accurately detect and segment MNV in eyes with exudative AMD from a control group of eyes that present with macular edema from either DME or RVO. Higher scan sampling density improved the aiMNV sensitivity for MNV detection.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Pages 378-385"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Fluid and Thickness Fluctuations in Archway Trial for Port Delivery System with Ranibizumab versus Monthly Ranibizumab Injections","authors":"Veeral S. Sheth MD ,&nbsp;Nancy M. Holekamp MD ,&nbsp;Arshad M. Khanani MD, FASRS ,&nbsp;Aleksandra Rachitskaya MD, FASRS ,&nbsp;Steven Blotner MS ,&nbsp;Shamika Gune MD ,&nbsp;Dominic Heinrich MD ,&nbsp;Katie F. Maass PhD ,&nbsp;Usha Chakravarthy MD, PhD","doi":"10.1016/j.oret.2024.10.015","DOIUrl":"10.1016/j.oret.2024.10.015","url":null,"abstract":"<div><h3>Purpose</h3><div>To determine proportion of eyes with neovascular age-related macular degeneration (nAMD) with retinal fluid and central subfield thickness (CST) fluctuations and evaluate their impact on best-corrected visual acuity (BCVA) in eyes treated with the Port Delivery System with ranibizumab (PDS) versus monthly intravitreal ranibizumab injections.</div></div><div><h3>Design</h3><div>Post hoc analyses of phase 3 Archway trial (NCT03677934).</div></div><div><h3>Participants</h3><div>Adults with nAMD responsive to anti-VEGF therapy.</div></div><div><h3>Intervention</h3><div>Four hundred eighteen patients randomized 3:2 to the PDS (100 mg/mL) with refill-exchanges every 24 weeks (Q24W) or monthly intravitreal ranibizumab (0.5 mg) for 96 weeks.</div></div><div><h3>Outcomes</h3><div>Proportion of eyes in each treatment arm with subretinal and/or intraretinal fluid (SRF/IRF) overall and in central 1 mm; BCVA changes from baseline by treatment arm and fluid presence/location; proportion of eyes with CST fluctuations from baseline to week 48, week 48 to 96, and baseline to week 96; effects of CST fluctuations on BCVA.</div></div><div><h3>Results</h3><div>Four hundred fifteen eyes were assessed. In the PDS versus monthly ranibizumab arm, proportion of eyes with SRF/IRF, central SRF, and central IRF were 47.6% versus 50.9%, 29.0% versus 19.2%, and 11.7% versus 12.6% at baseline, and 57.8% versus 56.1%, 21.6% versus 14.8%, and 7.0% versus 8.4% at week 96, respectively. BCVA changes from baseline to week 96 were −1.1 letters with the PDS versus −1.4 with monthly ranibizumab in eyes with SRF/IRF, and −1.9 versus −1.8 in eyes with central SRF. In eyes with central IRF, BCVA changes from baseline to week 96 were −2.1 with the PDS versus −6.9 with monthly ranibizumab, respectively (mean BCVA at 96 weeks 68.9 [20/40] vs. 64.6 [20/50]). CST fluctuations occurred in 32.1% and 29.7% of PDS versus monthly ranibizumab eyes; corresponding BCVA changes from baseline to week 96 were −2.5 versus −2.6 (mean BCVA at 96 weeks 72.7 [20/35] vs. 71.5 [20/38]).</div></div><div><h3>Conclusions</h3><div>Port Delivery System with ranibizumab Q24W maintained BCVA to 96 weeks regardless of SRF/IRF, central SRF, central IRF, or CST fluctuations, comparable with monthly ranibizumab, thus supporting the use of the PDS in stabilizing retinal anatomy without the need for monthly treatment in patients with nAMD.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Pages 330-342"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell-free DNA from Aqueous and Dilute Vitreous Improves Detection of Vitreoretinal Lymphoma","authors":"Noah A. Brown MD ,&nbsp;Daniel A. Balikov MD, PhD ,&nbsp;Daniel Boyer MD, PhD ,&nbsp;Bryan L. Betz PhD ,&nbsp;Amir Behdad MD ,&nbsp;Thérèse M. Sassalos MD ,&nbsp;Hakan Demirci MD ,&nbsp;Rajesh C. Rao MD","doi":"10.1016/j.oret.2024.12.010","DOIUrl":"10.1016/j.oret.2024.12.010","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Pages 402-404"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Sánchez-Vela at al.: Reverse pupillary block after implantation of a sutureless scleral fixation Carlevale intraocular lens (Ophthalmology Retina. 2025;9:322-329)","authors":"Fikret Ucar MD","doi":"10.1016/j.oret.2024.12.016","DOIUrl":"10.1016/j.oret.2024.12.016","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Page e27"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for the Diagnosis, Management, and Study of Autoimmune Retinopathy from the American Academy of Ophthalmology's Task Force.","authors":"Bobeck S Modjtahedi, Alan G Palestine, Lee M Jampol, David Sarraf, H Nida Sen, Lucia Sobrin, John J Chen, Paul Yang, Grazyna Adamus, Donald S Fong, Cynthia X Qian, Flora Lum","doi":"10.1016/j.oret.2025.03.024","DOIUrl":"10.1016/j.oret.2025.03.024","url":null,"abstract":"<p><strong>Purpose: </strong>The American Academy of Ophthalmology created a Task Force to advance the understanding of autoimmune retinopathy (AIR) and provided guidelines on the diagnosis and management of this complex disorder.</p><p><strong>Design: </strong>A search on PubMed and Google Scholar of English-language studies was conducted without date restrictions. The Task Force reviewed the current literature and formulated an expert consensus on the management of AIR as well as recommendations for future efforts to improve our understanding of this condition.</p><p><strong>Results: </strong>Key clinical and imaging features are discussed, and a new diagnostic framework is proposed based on the likelihood of AIR (probable AIR, possible AIR, and unlikely AIR) to provide a more standardized approach for categorizing disease. Patients who possess all the following features can be categorized as having probable AIR: (1) signs of disease progression based on subjective symptoms and objective testing within 6 months; (2) examination with <1+ anterior chamber cells, vitreous cells, or vitreous haze; (3) OCT with outer retinal disruption and loss of the external limiting membrane/outer retinal bands/ellipsoid zone often relatively sparing the fovea; (4) characteristic fundus autofluorescence abnormalities; (5) full-field electroretinogram (ERG) with reduction of both rod and cone responses; and (6) positive antiretinal antibodies. Those with some but not all of these features, or with otherwise atypical presentations, can be classified as possible AIR. Features that would make AIR unlikely and should elicit strong suspicion for alternative diagnoses are as follows: (1) slowly progressive symptoms or changes on testing taking place over the years; (2) retinal examination with bone spicules, retinal vascular sheathing, or retinal hemorrhages; (3) examination with >1+ anterior chamber cells, vitreous cells, or vitreous haze; (4) OCT changes predominantly at the level of the retinal pigment epithelium (RPE) or areas of focal/sharply delineated outer retinal/RPE atrophy; (5) fluorescein angiography with diffuse retinal vasculitis or large areas of nonperfusion; or (6) a normal full-field ERG (even with an abnormal multifocal ERG).</p><p><strong>Conclusions: </strong>These criteria will allow for better classification of patients reported in the literature and improve communication between clinicians. Further study is necessary to optimize the approach for managing AIR and will require collaborative multicenter efforts.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Segmental Optic Nerve Hypoplasia","authors":"Savithiri Palanivel DOMS, DNB,&nbsp;Anand Rajendran DNB, FRCS","doi":"10.1016/j.oret.2024.08.006","DOIUrl":"10.1016/j.oret.2024.08.006","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Page e31"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient Macular Edema Associated with Aberrant Retinal Macrovessel","authors":"Elton Zhou MD,&nbsp;Leslie Irizarry,&nbsp;Osman Cekic MD, PhD","doi":"10.1016/j.oret.2024.08.022","DOIUrl":"10.1016/j.oret.2024.08.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Page e37"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Modified Intravitreal Methotrexate Protocol for the Prevention of Proliferative Vitreoretinopathy after Silicone Oil Removal","authors":"Tianyu Liu MD ,&nbsp;Margaret Runner MD ,&nbsp;Tamer H. Mahmoud MD, PhD ,&nbsp;Antonio Capone Jr. MD ,&nbsp;Kimberly A. Drenser MD, PhD ,&nbsp;Sandeep Randhawa MD ,&nbsp;George A. Williams MD ,&nbsp;Lisa J. Faia MD","doi":"10.1016/j.oret.2024.10.006","DOIUrl":"10.1016/j.oret.2024.10.006","url":null,"abstract":"<div><h3>Objective</h3><div>To utilize a modified intravitreal (IVT) methotrexate (MTX) protocol for the prevention of proliferative vitreoretinopathy (PVR) after silicone oil (SO) removal (SOR).</div></div><div><h3>Design</h3><div>Single-center nonrandomized retrospective comparative case series.</div></div><div><h3>Subjects</h3><div>Eyes with grade C PVR who underwent retinal detachment (RD) repair and SO placement between 2019 and 2022 with ≥6 months of follow-up after SOR. A control group of age- and sex-matched eyes was included.</div></div><div><h3>Methods</h3><div>Eyes were treated with 1 of 2 MTX protocols. Eyes in Group 1 received 6 IVT MTX injections after SO placement and another 6 IVT MTX injections after SOR. Eyes in Group 2 received 6 IVT MTX after SO placement only. Each series of 6 IVT MTX injections (400 μg/0.1 mL) consisted of 3 injections every 2 weeks followed by 3 injections every 4 weeks.</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome was the retinal attachment rate at 6 months post-SOR without redetachment or reoperation. Secondary outcomes included change in visual acuity and rates of complications after SOR.</div></div><div><h3>Results</h3><div>Fifty-two eyes of 52 patients (13 Group 1, 13 Group 2, 26 control) (mean age 59.8 years, 80.8% male) were included with a mean follow-up of 31.0 months. In aggregate, Group 1 and Group 2 eyes received a median (interquartile range [IQR]) of 6 (5.25, 7) IVT MTX injections pre-SOR; eyes in Group 1 received a median (IQR) of 5 (3, 6) IVT MTX injections post-SOR. Twelve (92.3%) Group 1 eyes, 11 (84.6%) Group 2 eyes, and 21 (80.8%) control eyes had primary retinal attachment at 6 months post-SOR (<em>P</em> &gt; 0.05). Visual acuity outcomes did not significantly differ between groups (<em>P</em> &gt; 0.05). Rates of epiretinal membrane (ERM) and cystoid macular edema (CME) were significantly lower in Group 1 eyes (7.7% and 15.4%) compared with Group 2 (53.8% and 92.3%) and control (44.3% and 65.4%) eyes, respectively (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>The use of IVT MTX injections in eyes with PVR undergoing RD repair was associated with a high rate of primary retinal attachment after SOR. Eyes that received IVT MTX injections after SOR had significantly lower rates of ERM and CME than eyes that did not.</div></div><div><h3>Financial Disclosure(s)</h3><div>The author(s) have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 4","pages":"Pages 314-321"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}